Rate of serious spinal adverse events (probable cases per 1 000 000 patients) reported by route of administration and anatomical site of injection
| Spinal level | Total | Transforaminal (N=523 601) | Non-transforaminal (N=832 356) | ||||||
| Events (n) | Eligible patients (n) | Rate (95% CI) | Events (n) | Eligible patients (n) | Rate (95% CI) | Events (n) | Eligible patients | Rate (95% CI) | |
| Total | 11 | 1 355 957 | 8.1 (4.5 to 14.5) | 2 | 523 601 | 3.8 (1.1 to 13.9) | 9 | 832 356 | 10.8 (5.7 to 20.6) |
| Cervical/thoracic | 2 | 22 000 | 90.9 (24.9 to 331.4) | 3 | 148 271 | 20.2 (6.9 to 59.5) | |||
| Particulate | 5 | 170 271 | 29.4 (12.5 to 68.8) | 1 | 13 120 | 76.2 (13.5 to 431.7) | 2 | 128 843 | 15.5 (4.3 to 56.6) |
| Non-particulate | 1 | 8880 | 112.6 (19.9 to 637.7) | 1 | 19 428 | 51.5 (9.1 to 291.5) | |||
| Lumbar/sacral | 0 | 501 601 | 0.0 (0.0 to 7.7) | 6 | 684 085 | 8.8 (4.0 to 19.1) | |||
| Particulate | 6 | 1 185 686 | 5.1 (2.3 to 11.0) | 0 | 411 191 | – | 6 | 650 404 | 9.2 (4.2 to 20.1) |
| Non-particulate | 0 | 90 410 | – | 0 | 33 681 | – | |||